LIPOPROTEIN-(A) IN THYROID-DYSFUNCTION BEFORE AND AFTER TREATMENT

被引:22
作者
SPANDRIO, S [1 ]
SLEIMAN, I [1 ]
SCALVINI, T [1 ]
SALVI, A [1 ]
DISTEFANO, O [1 ]
PAGLIAINI, R [1 ]
BALESTRIERI, GP [1 ]
机构
[1] UNIV BRESCIA,MED CLIN,BRESCIA,ITALY
关键词
LIPOPROTEIN-(A); HYPERTHYROIDISM; HYPOTHYROIDISM;
D O I
10.1055/s-2007-1002182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alterations of the lipid profile are a well known phenomenon in thyroid dysfunction. Thyroid hormones regulate lipid metabolism through various mechanisms, but a key role is played by the LDL receptor pathway. Thyroid hormone influence on Lipoprotein (a) (Lp[a]) metabolism is unknown; therefore we studied Lp(a) concentrations in a group of 29 hypothyroid patients with post-surgical hypothyroidism and in a group of 14 hyperthyroid subjects with Graves' disease before and after the thyroid function was normalized by treatment. In hypothyroid patients total and LDL-cholesterol markedly decreased after T4 treatment (342 +/- 78 mg/dl before and 193 +/- 46 mg/dl after; 225 +/-72 mg/dl before, 111 +/- 43 mg/dl after respectively, p<0.001). Also HDL-cholesterol and triglycerides decreased (from 75 +/- 22 mg/dl to 56 +/- 18 mg/dl and from 182 +/- 87 mg/dl to 112 +/- 42 mg/dl respectively, p<0.001). Lp(a) showed minor but not significant variations (median values 80 mg/l before 55 mg/l after treatment, p: N.S.). In hyperthyroid patients total and LDL-cholesterol increased after methimazole treatment (from 148 +/- 49 mg/dl before to 254 +/- 67 mg/dl after and from 87 +/- 38 mg/dl before to 178 +/- 51 mg/dl after, p<0.001). HDL-cholesterol increased (from 39 +/- 9 to 50 +/- 15, p<0.01) while triglycerides were unchanged. Lp(a) levels slightly rose (median values 57 mg/l before 84 mg/l after treatment, p<0.05). These data suggest that the influence of thyroid hormones on Lp(a) metabolism is of minor entity and probably does not operate through the LDL receptor pathway.
引用
收藏
页码:586 / 589
页数:4
相关论文
共 18 条
[1]  
ABRAMS JJ, 1981, J LIPID RES, V22, P323
[2]  
AGDEPPA D, 1979, J CLIN ENDOCR METAB, V49, P727
[3]   REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL [J].
ALBERS, JJ ;
TAGGART, HM ;
APPLEBAUMBOWDEN, D ;
HAFFNER, S ;
CHESNUT, CH ;
HAZZARD, WR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 795 (02) :293-296
[4]  
ALBERS JJ, 1990, CLIN CHEM, V36, P2019
[5]  
ARMSTRONG VW, 1985, J LIPID RES, V26, P1314
[6]   GENETICS OF THE QUANTITATIVE LP(A) LIPOPROTEIN TRAIT .3. CONTRIBUTION OF LP(A) GLYCOPROTEIN PHENOTYPES TO NORMAL LIPID VARIATION [J].
BOERWINKLE, E ;
MENZEL, HJ ;
KRAFT, HG ;
UTERMANN, G .
HUMAN GENETICS, 1989, 82 (01) :73-78
[7]  
GOULD RG, 1959, HORMONES ATHEROSCLER, P75
[8]   HDL CLEARANCE AND RECEPTOR-MEDIATED CATABOLISM OF LDL ARE REDUCED IN HYPOTHYROID RATS [J].
GROSS, G ;
SYKES, M ;
ARELLANO, R ;
FONG, B ;
ANGEL, A .
ATHEROSCLEROSIS, 1987, 66 (03) :269-275
[9]   OVEREXPRESSION OF HUMAN LOW-DENSITY-LIPOPROTEIN RECEPTORS LEADS TO ACCELERATED CATABOLISM OF LP(A) LIPOPROTEIN IN TRANSGENIC MICE [J].
HOFMANN, SL ;
EATON, DL ;
BROWN, MS ;
MCCONATHY, WJ ;
GOLDSTEIN, JL ;
HAMMER, RE .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1542-1547
[10]   CATABOLISM OF LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS [J].
KNIGHT, BL ;
PEROMBELON, YFN ;
SOUTAR, AK ;
WADE, DP ;
SEED, M .
ATHEROSCLEROSIS, 1991, 87 (2-3) :227-237